Delving into the Latest Updates on Xuzhou Central Hospital with Synapse

Overview

Tags

Neoplasms

Recombinant polypeptide

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Recombinant polypeptide	1

Top 5 Target	Count

GPER1(G protein-coupled estrogen receptor 1)	1

OBJECTIVEA meta-analysis was conducted to assess the efficacy and safety of cryoablation (CRA) compared with radiofrequency ablation (RFA).METHODSA systematic search of PubMed, EMBASE, Cochrane Library, Wanfang, CNKI, and VIP databases was conducted to identify clinical controlled studies comparing CRA versus RFA for hepatic malignancies up to July 2022. The meta-analysis was performed using RevMan 5.3.RESULTSA comprehensive analysis was conducted on 8 clinical controlled studies involving a total of 943 patients. There were no significant differences in the incidence of complications, complete ablation of lesions, local recurrence, and 1-year survival between the CRA and RFA groups (OR = 0.98, 95%CI: 0.61-1.55, p = 0.92; OR = 1.08, 95%CI: 0.62-1.90, p = 0.78; OR = 1.28, 95%CI: 0.49-3.36, p = 0.61; and OR = 1.14, 95%CI: 0.63-2.06, p = 0.66, respectively).CONCLUSIONThe efficacy and safety profile of CRA was comparable to that of RFA in the context of ablation therapy for hepatic malignancies. These findings suggested that CRA may be a valuable alternative to RFA in the treatment of hepatic malignancies.

31 Dec 2024·BioengineeredQ4 · BIOLOGY

MicroRNA-4521 targets hepatoma up-regulated protein (HURP) to inhibit the malignant progression of breast cancer

Q4 · BIOLOGY

ArticleOA

Author: Peng, Sen ; Li, Changwen ; Tang, Chuangang

Changwen Li, Sen Pengb, and Chuangang Tanga. MicroRNA-4521 targets hepatoma up-regulated protein (HURP) to inhibit the malignant progression of breast cancer. Bioengineered. 2021 Oct. doi: 10.1080/21655979.2021.1996016.Since publication, significant concerns have been raised about the compliance with ethical policies for human research and the integrity of the data reported in the article.When approached for an explanation, the authors provided some original data but were not able to provide all the necessary supporting information. As verifying the validity of published work is core to the scholarly record's integrity, we are retracting the article. All authors listed in this publication have been informed.We have been informed in our decision-making by our editorial policies and the COPE guidelines.The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as 'Retracted.'

01 Dec 2024·International Immunopharmacology

Therapeutic vaccine targeting dual immune checkpoints induces potent multifunctional CD8+ T cell anti-tumor immunity

Article

Author: Lu, Zheng ; Chai, Dafei ; Zheng, Yanyan ; Shao, Yingxiang ; Wang, Gang ; Fang, Lin ; Zheng, Junnian ; Ding, Jiage ; Lu, Bowen ; Zhu, Fei ; Zhao, Guangya

BACKGROUNDVaccines targeting immune checkpoints represent a promising immunotherapeutic approach for solid tumors. However, the therapeutic efficacy of dual targeting immune checkpoints is still unclear in renal carcinoma.METHODSAn adenovirus (Ad) vaccine targeting B7H1 and B7H3 was developed and evaluated for its therapeutic efficacy in subcutaneous, lung metastasis or orthotopic renal carcinoma mouse and humanized models using flow cytometry, Enzyme-linked immunosorbent spot (ELISPOT), cytotoxic T lymphocyte (CTL) killing, cell deletion, hematoxylin and eosin (HE) staining, and immunohistochemistry (IHC) assays.RESULTSThe Ad-B7H1/B7H3 immunization effectively inhibited tumor growth and increased the induction and percentages of CD8⁺ T cells in subcutaneous tumor models. The vaccine enhanced the induction and maturation of CD11c⁺ or CD8⁺CD11c⁺ cells, promoting tumor-specific CD8⁺ T cell immune responses. This was evidenced by increased proliferation of CD8⁺ T cells and enhanced CTL killing activity. Deletion of CD8⁺ T cells in vivo abolished the anti-tumor effect of the Ad-B7H1/B7H3 vaccine, highlighting the pivotal role of functional CD8⁺ T cell immune responses. Moreover, significant therapeutic efficacy of the Ad-B7H1/B7H3 vaccine was observed in lung metastasis, orthotopic, and humanized tumor models through multifunctional CD8⁺ T cell immune responses.CONCLUSIONSThe Ad vaccine targeting dual immune checkpoints B7H1 and B7H3 exerts a potent therapeutic effect for renal carcinoma and holds promise for solid tumor treatment.

100 Deals associated with Xuzhou Central Hospital

Login to view more data

100 Translational Medicine associated with Xuzhou Central Hospital

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

Login to view more data